Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.41 |
| ▸ | CNR2 | P34972 | 9/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7538926 | 0.90 | CNR1 (0.40) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL7543264 | 0.83 | UTS2R (0.38) | CNR1CNR2MEN1KMT2A | |
| SCHEMBL7542553 | 0.82 | NR4A2 (0.43) | CNR1CNR2MEN1KMT2ANPC1 | |
| SCHEMBL7588335 | 0.80 | CNR1 (0.39) | CNR1CNR2MRGPRX4 | |
| SCHEMBL7538938 | 0.79 | NR4A2 (0.45) | CNR1MRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL7542604 | 0.79 | PPARG (0.41) | CNR1CNR2MEN1KMT2APOLB | |
| SCHEMBL7564669 | 0.77 | PPARG (0.45) | CNR1 | |
| SCHEMBL7535741 | 0.77 | PPARG (0.44) | CNR1MEN1KMT2A | |
| SCHEMBL7535851 | 0.76 | PPARG (0.44) | CNR1MEN1KMT2A | |
| SCHEMBL7539911 | 0.74 | ATM (0.40) | CNR1CNR2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | PLA2G4B, PLA2G1B, PLA2R1 | CNR1 323/4885CNR2 383/4885MRGPRX4 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.